Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 0.69 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.69 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27937302 | 0.94 | AGTR1 (0.69) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Potassium Ion SCHEMBL16872384 | 0.93 | AGTR1 (0.60) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL10109219 | 0.93 | AGTR1 (0.72) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL28484414 | 0.92 | AGTR1 (0.59) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL991961 | 0.92 | AGTR1 (0.59) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL1275437 | 0.89 | AGTR1 (0.55) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL4603059 | 0.89 | AGTR1 (0.53) | AGTR1AGTR2 | |
| SCHEMBL8199740 | 0.88 | AGTR1 (0.73) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL1445570 | 0.88 | AGTR1 (0.53) | AGTR1AGTR2 | |
| SCHEMBL14258672 | 0.88 | AGTR1 (0.72) | AGTR1AGTR2ABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106083833-B | Purification method of trityl olmesartan medoxomil | 浙江华海药业股份有限公司 | 2020-12-08 | — | — | CN | claimed |
| EP-1916246-A2 | An improved process for the preparation of olmesartan medoxomil | Cadila Pharmaceuticals Limited (IN) | 2008-04-30 | — | — | EP | claimed |
| CN-106083833-B | Purification method of trityl olmesartan medoxomil | 浙江华海药业股份有限公司 | 2020-12-08 | — | — | CN | disclosed |
| US-8252825-B2 | Angiotensin II receptor antagonists | NICOX (IT) | 2012-08-28 | — | — | US | disclosed |
| WO-2011007368-A3 | AN IMPROVED PROCESS FOR PREPARATION OF OLMESARTAN | CADILA HEALTHCARE LIMITED (IN) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011007368-A2 | AN IMPROVED PROCESS FOR PREPARATION OF OLMESARTAN | CADILA HEALTHCARE LIMITED (IN) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011007368-A2 | AN IMPROVED PROCESS FOR PREPARATION OF OLMESARTAN | CADILA HEALTHCARE LIMITED (IN) | 2011-01-20 | — | — | WO | disclosed |
| US-20100273845-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-10-28 | — | — | US | disclosed |
| EP-2225225-A2 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-09-08 | — | — | EP | disclosed |
| WO-2010015447-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2010-02-11 | — | — | WO | disclosed |
| WO-2009070241-A2 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| EP-1916246-A2 | An improved process for the preparation of olmesartan medoxomil | Cadila Pharmaceuticals Limited (IN) | 2008-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273845-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR2, AGTR1, REN | AGTR1 2/4885AGTR2 1/4885ABCC3 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.